Wondering if UiPath is still a smart way to play the AI and automation theme, or if the easy money has already been made? Here is a look at the numbers so you can decide if the current price really ...

Retatrutide, a new weight loss from Eli Lilly, isn’t even out yet. For tht matter, it hasn’t even finished human clinical trials. But it’s already garnered a cult-like following, Wired reports, with ...

Temporarily shutting down a "lazy eye" triggers a burst of neuronal activity that reverses the condition in animal experiments, a study shows. When you purchase through links on our site, we may earn ...

UiPath Inc. (NYSE: PATH) stock jumped in Wednesday's extended trading after the company released its third quarter earnings report, beating expectations on the top and bottom lines. Here's a look at ...

About The Study: During 2012 to 2023, the prevalence of injecting methamphetamine only or both methamphetamine and opioids increased significantly among people who inject drugs entering treatment, ...

Pluribus Episode 4, “Please, Carol,” took viewers and characters on yet another a wild ride. But this time, a hospital, needles, drugs, and lots of tears were involved. Pluribus Episode 4 spoilers ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

A new proof-of-concept attack shows that malicious Model Context Protocol servers can inject JavaScript into Cursor’s browser — and potentially leverage the IDE’s privileges to perform system tasks.

There may be no enterprise job today that can’t be enhanced through the use of automation and AI, and agentic AI represents the next step toward fully realizing that potential. So says Daniel Dines, ...

UiPath could become the connective tissue linking the software sprawl that companies face. AI is helping UiPath expand the boundaries of traditional robotic process automation. Its focus on secure, ...

Those of us who work as drug journalists are accustomed to witnessing the limits of human creativity, both at its most beautiful and its darkest. It’s the latter that prove most challenging to the ...

UiPath stock rallied after announcing several new partnerships. The company is looking to reinvent itself as an agentic automation company. The stock is cheap and could have nice upside if these ...